Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $34.82 Consensus Price Target from Analysts

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) have earned a consensus rating of “Moderate Buy” from the sixteen analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $35.00.

Several brokerages have issued reports on DNLI. Morgan Stanley lifted their price target on shares of Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. UBS Group initiated coverage on shares of Denali Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating on the stock. The Goldman Sachs Group boosted their price objective on shares of Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Robert W. Baird boosted their price objective on shares of Denali Therapeutics from $32.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday. Finally, BTIG Research boosted their price objective on shares of Denali Therapeutics from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Wednesday, March 25th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. State of Wyoming increased its stake in shares of Denali Therapeutics by 24.7% during the 4th quarter. State of Wyoming now owns 2,686 shares of the company’s stock worth $44,000 after purchasing an additional 532 shares during the last quarter. Intrust Bank NA increased its stake in shares of Denali Therapeutics by 5.6% during the 4th quarter. Intrust Bank NA now owns 11,164 shares of the company’s stock worth $184,000 after purchasing an additional 589 shares during the last quarter. ADAR1 Capital Management LLC increased its stake in shares of Denali Therapeutics by 1.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 52,116 shares of the company’s stock worth $860,000 after purchasing an additional 600 shares during the last quarter. Pier 88 Investment Partners LLC increased its stake in shares of Denali Therapeutics by 1.1% during the 4th quarter. Pier 88 Investment Partners LLC now owns 68,200 shares of the company’s stock worth $1,126,000 after purchasing an additional 760 shares during the last quarter. Finally, Tudor Investment Corp ET AL increased its stake in shares of Denali Therapeutics by 1.7% during the 3rd quarter. Tudor Investment Corp ET AL now owns 56,368 shares of the company’s stock worth $818,000 after purchasing an additional 920 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Denali Therapeutics Trading Up 0.2%

Shares of NASDAQ DNLI opened at $19.41 on Friday. The company’s fifty day moving average is $20.43 and its 200-day moving average is $18.17. The stock has a market cap of $3.08 billion, a price-to-earnings ratio of -6.54 and a beta of 1.10. Denali Therapeutics has a twelve month low of $10.80 and a twelve month high of $23.77. The company has a quick ratio of 9.16, a current ratio of 9.16 and a debt-to-equity ratio of 0.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter in the prior year, the firm earned ($0.67) EPS. Equities research analysts predict that Denali Therapeutics will post -2.71 EPS for the current year.

About Denali Therapeutics

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.